INTRODUCTION
The interactions of neutrophils with endothelial cells that line the blood vessels are necessary for their migration to sites of inflammation. This dynamic process follows a multistep sequence that is initiated by initial tethering and rolling mediated by P-and Eselectins expressed on activated venules and their glycoconjugated ligands on leukocytes Patients also suffer from severe mental retardation, suggesting that fucosylated glycoproteins and/or glycolipids are important for brain function. All five LADII patients described to date are from Middle Eastern descent (4 Arabs and 1 Turkish) 16 . In search for the defective pathway in the fucose metabolism, it was found that when fibroblasts and lymphoblastoid cells derived from a LADII patient were grown in the presence of millimolar concentrations of fucose, cell surface fucosylation could be restored 17 . Following this observation, Marquardt et al. administered orally L-fucose to the Turkish LAD II patient and observed a remarkable clinical response 18 . Within days after fucose intake, neutrophil counts normalized and functional E-and P-selectin ligands were expressed on myeloid cells. However, the Arab subjects have not responded to oral fucose therapy 19, 20 , suggesting a different molecular basis for their disease.
The gene defective in LADII was recently cloned and encodes a putative GDPfucose transporter which is predicted to span the Golgi membrane ten times 21, 22 . Single and distinct missense mutations were identified in Arab and Turkish kindred, thus providing a molecular explanation for the differential response to fucose. In the present report, we describe a new case of leukocyte adhesion deficiency type II in a patient of Brazillian origin without any known Middle Eastern descent. The disease in this patient stems from a novel single nucleotide deletion leading to frameshift and premature arrest in the translation of the GDP-fucose transporter gene. We show that this patient responds well to fucose therapy and that partial restoration of P-selectin-ligand function on the patient's neutrophils correlates with an increased ability to roll in cremasteric venules of immunodeficient NOD/SCID mice. We further demonstrate that induction of fucosylated
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Isolation of neutrophils
Neutrophils were purified from anticoagulated venous blood samples from the LAD II patient or healthy adult volunteers in a Histopaque™ 1119 (d=1.119 g/ml; Sigma Diagnostics; St. Louis, MO) and Ficoll-Paque (d=1.077 g/ml; Amersham Pharmacia Biotec, Upsala, Sweden) discontinuous gradient and washed in PBS containing 2 mM EDTA and 0.5% BSA (PEB buffer). For intravital microscopy experiments, purified human neutrophils were fluorescently labeled by incubation with 33 µM carboxyfluorescein succinimidyl ester (CFSE; Molecular Probes, Eugene, OR) for 30 min at 6ºC, and washed thrice in RPMI before injection into mice via a carotid artery catheter.
Human blood samples were obtained in accordance with protocols approved by the Internal Review Board of Mount Sinai.
Antineutrophil antibody and H antigen Assays
Antineutrophil antibody activity in the patient´s serum was detected by flow cytometry. Purified neutrophils from healthy donors were incubated with a 1:100 dilution of sera obtained from the peripheral blood of healthy donors or the LAD II patient, washed, and further incubated with Cy5-conjugated anti-human IgG antibody.
After a final wash, cells were analyzed on a FACScalibur® flow cytometer (Becton Dickinson) or subjected to cytospin and prepared for fluorescence microscopy as indicated below. Granulocyte Agglutination (GA) and Monoclonal Antibody Specific Immobilization of Neutrophil Antigens (MAIGA) assays were also performed in parallel (Neutrophil Serology Laboratory, American Red Cross, St. Paul, MN) using a panel of donor neutrophils serologically phenotyped for the NA1, NA2, NB1, NB2, 5A, 5B, 9A 
Cell culture and generation of the lymphoblastoid cell line
Fibroblasts were obtained from a skin biopsy of the LADII patient and cultured in DMEM medium (CellGro, Herndon, VA) containing 10% FCS (Hyclone, Logan, UT) and antibiotics. For the generation of a lymphoblastoid cell line, low-density mononuclear cells (MNC) were collected after centrifugation at 250 g over Ficoll-Paque of a blood sample from the LADII patient. B lymphoid cells were transformed and selected by plating MNC in 10 ml of RPMI 1640 plus 10% FCS also containing 2 µg/ml Cyclosporin A (CSA; Novartis Pharmaceutical Corp, East Hanover NJ), 10 µg/ml phytohemagglutinin (Gibco, Grand Island, NY) and 1 ml of Epstein Barr Virus (EBV) supernatant. After 10 days of culture, lymphoid colonies were expanded and selected in RPMI plus 10% FCS containing 2 µg/ml of CSA. The transformed LADII-derived lymphoid cell line was further cultured in RMPI plus 10% FCS and antibiotics. The B7 EBV-transformed lymphoblastoid cell line established from a normal donor (generous 
Flow cytometry and selectin chimera binding assay
Cells were washed in PEB buffer before incubation with 15 µg/ml of biotinylated Aleuria aurantia lectin or 10 µg/ml of primary antibodies. After washing in PEB buffer, the cells were incubated with a 1:100 dilution of FITC-conjugated streptavidin or Cy-5-conjugated anti-rat antibody (both from Jackson Immunoresearch, West Grove, PA), respectively. After a final wash, cells were analyzed by flow cytometry. All incubations were performed for 15 min at 6ºC.
Selectin chimera binding assays were performed as described in 23 . Briefly, neutrophils were incubated for 15 min at 6ºC in staining buffer (RPMI containing 5% FCS and 0.05% NaN 3 ) containing a human P-selectin-IgG that had been preconjugated to 
Intravital microscopy experiments
NOD/SCID animals were prepared for intravital microscopy of the cremaster muscle as previously described 24 . Prior to the exteriorization of the cremaster muscle, the trachea was cannulated to allow spontaneous respiration and a PE-10 catheter (Becton parameters and number of rolling cells were calculated as described previously 23 .
Statistical Analysis
All values are reported as mean ± SEM. Statistical significance was analyzed using the Student t test.
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RESULTS

A new case of leukocyte adhesion deficiency type II
A 7 month old boy of consanguineous Brazilian descent with microcephaly, multiple choroid plexus cysts, hypospadias, bilateral hydronephrosis and developmental delay presented for evaluation of recurrent infections, including four hospitalizations for fever, gastroenteritis and severe cellulitis. There was no history of immunodeficiency in the family. Total white blood cell counts ranged from 30,000 to 83,000 cells/ml and absolute neutrophil counts from 6,000 to 56,000 cells/ml. Fever episodes rapidly responded to antibiotic therapy and blood cultures were always sterile. Immunologic evaluation of T-cell numbers and function, immunoglobulin levels and CD11/18 expression were all within normal range. LADII was diagnosed by the absence of the sialyl Lewis X (sLe X ) antigen, impaired E-and P-selectin binding (see below) and presence of the Bombay blood type.
Cloning of the GDP-fucose transporter gene reveals a single base deletion before the sixth transmembrane domain
The gene responsible for the LADII syndrome has been recently shown to encode a putative Golgi GDP-fucose transporter whose structure predicts ten transmembrane domains. Sequencing of the GDP-fucose transporter from the genome of the two known families of LADII revealed single and distinct missense mutations. The Turkish patient had a C→T transition at base 439 which led to the substitution of an arginine for a cysteine (R147C) in the fourth transmembrane domain. Three Arab patients exhibited a and fucosylation activity was detected using Aleuria aurantia lectin (AAL) staining. As shown in Fig.2A , LADII fibroblasts transfected with wild-type cDNA exhibited a strong perinuclear AAL staining, similar to that previously shown for fibroblasts from normal donors or from LADII patients transfected with the wild-type GDP-FucTP gene 21 . In contrast, expression of the mutant cDNA in the patient's fibroblasts did not stain with the lectin (Fig. 2 C) , suggesting that the mutant GDP-FucTP gene is responsible for the fucosylation defect observed in the patient.
In vitro and in vivo response to fucose therapy
It has been previously reported that when fibroblasts, endothelial cells and lymphoblastoid cell lines derived from LADII patients are grown in the presence of fucose, carbohydrate structures containing fucose can be induced on the cell surface 17, 18 .
To evaluate the effect of fucose exposure on cells derived from our patient, we analyzed AAL binding to a B lymphoblastoid cell line by flow cytometry. As shown in Fig. 3 17, 18 and suggest that exposure to exogenous fucose can also restore fucosylation on LADII cells derived from this patient.
Since fucose therapy has previously been shown to be clinically effective in one case of LAD type II 18 , we initiated a treatment with fucose supplements. Oral administration of L-fucose was begun at a daily dose of 165 mg/kg divided 5 times per day and was increased progressively thereafter (Fig.4) . (Fig.5 ). These observations are in line with those obtained from the other LADII patient that responded to oral fucose 18 , in which E-selectin ligands were detected much later than P-selectin ligands after fucose treatment, and suggest a preferential incorporation of fucose in P-selectin glycoprotein ligands over E-selectin ligands.
For
Fucose therapy partially restores the ability of LADII neutrophils to roll in vivo
The marked improvement in neutrophil counts appeared to contrast with the selectin binding assays which only showed a partial rescue in selectin binding. To evaluate the ability of LADII leukocytes to roll in vivo, we isolated neutrophils from the LADII patient before and after fucose treatment. Normal neutrophils were purified in parallel from healthy controls. Purified neutrophils were fluorescently labeled and injected through the carotid artery of immunodeficient NOD/SCID mice. Neutrophil behavior was then assessed in cremasteric venules. Under these conditions, rolling is almost entirely mediated by endothelial P-selectin 26 . As shown in Fig.6A , the interacting flux of LADII neutrophils, before or 8 days after fucose treatment, was very low (2.3 ± 2.3% and 1.3 ± 1.3%, respectively) compared to the average observed with neutrophils from control donors (23.8 ± 5.6%). Stikingly, on day 16 after treatment, the percentage of interacting LADII neutrophils (29.8 ± 11%) was similar to that of controls. However, detailed analysis of videotapes demonstrated a clear difference in the quality of these interactions, in that fucose-treated LADII neutrophils interacted very briefly and for very short distances compared to the longer distances and times achieved by normal neutrophils, as depicted in the scattergram (Fig.6B ). Thus these data suggest that, although the behavior of fucose-treated neutrophils is clearly abnormal in vivo on day 16, a partial recovery of P-selectin ligands alone appears to be sufficient to restore leukocyte trafficking in LADII.
Fucose therapy induces auto-antibodies against neutrophils and erythrocytes
After 35 days of fucose therapy, the peripheral neutrophil counts decreased to levels below the adjusted normal counts (Fig.4, asterisk) . We suspected that the overcorrection in the neutrophil counts might have resulted from a decreased leukocyte halflife, perhaps due to the generation of auto-antibodies directed toward neoantigens expressed on the neutrophil surface. The dose of oral fucose was decreased from from 975 to 570 mg/kg/day and the patient's serum was evaluated for the presence of antineutrophil antibodies. Samples of control and patient's sera were incubated with purified neutrophils from healthy donors. Bound antibodies were detected using a Cy5-conjugated anti-human secondary antibody. As shown in Fig.7 , serum from day 41 fucose-treated LADII patient strongly stained neutrophils by flow cytometry. Cytospin preparations revealed a clustered-appearing membrane staining (Fig.7 , lower inset) which was specific since no such staining was observed when neutrophils were incubated with control serum (Fig.7, upper inset) . These results were confirmed by an independent reference laboratory (Neutrophil Serology Laboratory) which also demonstrated positive granulocyte agglutination assays (titre 1:32) at the nadir of neutropenia (data not shown).
Monoclonal antibody specific immobilization of neutrophil antigens (MAIGA) revealed that the autoantibody was not directed against the known neutrophil autoantigens NA1, NA2, NB1 and MART (not shown). Western blot analyses of neutrophil lysates in our laboratory have failed to reveal further information about the nature of the antigen.
The possible induction by fucose therapy of fucosylated antigens on the surface of erythrocytes was also a major clinical concern. This could lead to hemolysis since LADII patients have natural antibodies against the H antigen (Bombay phenotype).
Thus, we closely monitored hemoglobin, reticulocytes and haptoglobin levels, as well as the expression of fucosylated structures on the surface of the patient's erythrocytes using lectin staining. As shown in Fig.8 , no detectable AAL staining was observed on day 16 erythrocytes. However, starting from day 36 of fucose treatment up to the writing of this report (day 260), erythrocytes have stained positively with AAL. In addition, erythrocytes collected on day 189 reacted with two of three polyclonal anti-H sources.
However, direct antiglobulin (Coombs) tests were always negative and the patient never presented clinical evidence of auto-hemolysis. Taken together, these results, in contrast to a previous report 18 , demonstrate that fucose therapy in LADII may induce the expression of neoantigens which represent a risk for autoimmune phenomena. Because of clinical concerns, fucose therapy has been dose-adjusted to ensure an absolute neutrophil count of 1,500/µl or more (Fig.4) .
Psychomotor development is not improved by fucose therapy
In a manner similar to selectin ligands on leukocytes, psychomotor development was reported to improve in the patient with the R147C mutation 18, 21 but not in patients with T308R 19, 22 . We have not yet found evidence of psychomotor improvement in our patient whom, currently 15 months of age, has only recently started to crawl and babble.
In addition, our patient requires nasogastric tube feeding due to poor oropharyngeal coordination. Since only 25% of the serum fucose concentrations is found in the CSF 18 , it is possible that psychomotor improvement in our patient is hampered by the limited doses of administered fucose, owing to the aforementioned complications. Major advances have recently been made in the therapy and understanding of this disease. The first came from the observation that exogenous fucose could overcome the fucosylation defect in culture 17, 27 , and subsequently in a patient 18 . Treatment of the Turkish LADII subject with high doses of oral fucose produced a rapid lowering in the peripheral neutrophil counts which coincided with the induction of selectin ligand expression on leukocytes but, remarkably, did not induce the expression of the H antigen on erythrocytes. In addition, improved psychomotor development was seen as a result of fucose therapy. The fact that none of the Arab patients responded to fucose treatment 19, 20 suggested that LADII in the Arab kindred had a different molecular basis. The recent cloning of a putative GDP-fucose transporter, whose predicted structure encompasses ten transmembrane domains, brought a molecular explanation for this differential response since Arab and Turkish patients exhibited distinct mutations at the GDP-fucose transporter locus. The Turkish subject had a point mutation (C439T) causing the replacement of arginine 147 by a cysteine (R147C) in the fourth transmembrane domain of the transporter while the GDP-fucose transporter gene from three Arab patients contained a C923G mutation leading to a missense change from threonine to arginine (T308R) in the ninth transmembrane domain 21, 22, 25 . It was thought that the R147C mutation might lead to a reduced affinity of the transporter for GDPfucose which could be compensated by elevating cytosolic GDP-fucose levels, thus explaining the clinical response in the Turkish patient 29 . This hypothesis was supported by kinetic studies of GDP-fucose import into Golgi preparations in which both Arab-and Turkish-derived cell extracts showed a reduced V m of the saturable transport component, but only Golgi vesicles from the Turkish patient displayed a non-saturable component 20, 27 .
Since the patient described in this report came from a different ethnic background, we suspected that we might find a novel mutation. Indeed, sequencing of cDNA and genomic DNA from our patient and his parents revealed a single base deletion ( G588) before the sixth transmembrane domain, producing a shift in the open-reading frame and translation of 34 additional aminoacids before a stop codon (Fig.1) . Thus, at best, a severely truncated GDP-fucose transporter is expressed in our patient. Although our experiments using AAL staining suggest that the mutated transporter is non-functional, the limited sensitivity of this assay precludes a definitive conclusion on this issue.
Surprisingly, both the cells derived from our LADII patient and the clinical disease strongly responded to exogenous fucose. In a manner similar to the patient exhibiting the R147C mutation 18 , neutrophil counts of our patient rapidly normalized and the levels of soluble P-selectin binding to neutrophils reached 50% of that of control cells by day 40.
Given the robust response to exogenous fucose in the presence of the truncated transporter and the lack of structural homologies between G588 and R147C, we would argue that the residual transport activity might be mediated by alternate sugar transporter(s) whose activity cannot fully compensate for the mutated high-affinity transporter. Structure-function studies and gene knockout experiments will be useful to clarify whether G588 is indeed a null mutation and whether other fucose transport activities remain when the GDP-FucTP is completely eliminated.
The results of the selectin ligand assays suggested that only a partial restoration of P-selectin ligand activity can fully restore leukocyte homeostasis in LADII. We have correlated these in vitro assays with the behavior of fucose-treated LADII neutrophils in vivo using intravital microscopy. Our results show that despite a rapid and complete normalization of peripheral neutrophil counts, individual neutrophils still displayed marked defects in their ability to interact with P-selectin in cremasteric venules. These results also underscore the limitations in the sensitivity of fluid-phase binding assays since little difference was found in vitro between days 8 and 16 of fucose treatment (Fig.5 ) whereas significant improvement in the neutrophil interactions with the vessel wall (and sustained clinical response) were observed in vivo after day 8.
It is interesting that in contrast to P-selectin ligands, E-selectin ligands were never induced in our patient. In the report by Marquardt et al. 18 , E-selectin ligand expression required approximately a 2.5-fold higher dose of L-fucose (1665 mg/kg/day) than that needed to induce P-selectin ligands. These results suggest a preferential fucosylation of P-selectin ligands in neutrophils and that a higher Golgi concentration of fucose may be required for the fucosylation of E-selectin ligands. Preferential fucosylation has been described at the fucosyltransferase level. For example, the two known leukocyte fucosyltransferases (FucTIV and FucTVII) exhibit a differential preference for distal α2,3-sialyated acceptors (FucTVII > FucTIV) which are important for selectin ligands 30 .
Also, studies using murine neutrophils suggest that FucTVII preferentially fucosylates Pselectin glycoprotein ligand (PSGL-1) while FucTIV displays a preference for E-selectin ligand-1 (ESL-1) 31 . The lack of acquisition of functional E-selectin ligands in our patient might also be explained by other possibilities, including a difference in the kinetics of the mutated GDP-fucose transporter, the lower doses of fucose administered to our patient (due to the complications discussed below) or the behavior of alternate sugar transporters in the Golgi.
Importantly, we found that the induction of fucosylation in our patient produced two potentially serious complications. The first was the appearance of an autoimmune neutropenia which likely originates from the induction of neoantigens on the surface of neutrophils. The neutropenia responded to a reduction of the fucose intake (Fig.4) , which lends support to a cause-effect relationship between these two phenomena. sharply reduced on day 36 (to 580 mg/kg/day) in response to therapy-induced neutropenia (*). Neutrophil counts were determined using an automated cell counter.
The grey area marks the limits of normal absolute neutrophil counts for 1 year of age. 
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